Oncology News

Loxo Oncology, Inc. , a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced the pricing of its initial public offering of 5,261,538 shares of its common stock at a price to the public of $13.00 per share.

Sorrento Therapeutics, Inc. today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President.

HOPEWELL TOWNSHIP - When producers at Good Morning America asked news anchor Amy Robach to undergo her first mammogram in October on live television, her first reaction was, "'Are you kidding me? You want me to do what? There is no way,'" she said.

Bob Hugin, chief executive officer of Celgene Corp., reported second-quarter results of $748 million in net income.

As rates of other cancers have declined, rates of the deadliest form of skin cancer, melanoma, have increased more than 200 percent from 1973 to 2011, according to a new "Call to Action" report from the Surgeon General's Office.

AstraZeneca turned over $6.45 billion in the second quarter, up 4%, making half year sales 3% higher than the previous year.

Use of electroacupuncture - a form of acupuncture where a small electric current is passed between pairs of acupuncture needles - produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors to treat breast ... (more)

Former England and Newcastle United manager Sir Bobby Robson launches The Sir Bobby Robson Foundation in Newcastle with Dr Ruth Plummer and Bob Wilson on March 25, 2008 FACING CANCER for the fifth - and what he knew would be the final time - Sir Bobby Robson focused on a new goal far removed from the football field.

Julie Szasz with her daughter Eva at their home in St-Lazare. Szasz was diagnosed with breast cancer in 2010 that spread to her bones, but is in remission now.

Cold Genesys, Inc. , a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured Series A financing of $13.57 million from Ally Bridge Group.

This past April, just after the Centers for Medicare & Medicaid Services released the highly-anticipated 2012 Medicare provider charge data, the New York Times published an article," Sliver of Medicare Doctors Get Big Share of Payout ."

AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Top 7 Myths About HIPAA Security Risk Analysis : The Department of Health and Human Services Office for Civil Rights' pilot program to conduct HIPAA privacy and security audits showed that the top deficiency among audited organizations was the lack of a sufficient risk analysis plan.

Top 7 Myths About HIPAA Security Risk Analysis : The Department of Health and Human Services Office for Civil Rights' pilot program to conduct HIPAA privacy and security audits showed that the top deficiency among audited organizations was the lack of a sufficient risk analysis plan.

The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer , report researchers from the University of Pittsburgh Cancer Institute , partner with UPMC CancerCenter.

Maia Matteson and Kelly Geerdes, vacationing from Colorado, slap on the Hawaiian Tropic suntan lotion Tuesday overlooking Cowell Beach.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 .

Research Triangle Park's CivaTech Oncology raised $1.5 million in a new round and doubled the target for this latest round to $2 million.

Years ago, journalists who had breast cancer fought with words to inform other women with breast cancer that, in many cases, they didn't need a mastectomy.